Some progress has been made with the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor 2 (FGFR2) fusions as drivers in small subsets of intrahepatic cholangiocarcinoma tumors [5, 14–16]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.